Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

one way north, on todays latest news alone.

You are right, artey, it opens 5p up at 126...further uptrend for the day...BUY now before the announcement is made today

Looks good, lots of buying going on think news has leaked out in our favour (hopefully).

They are going bannanas over on ADVFN, seem to think that BPRG have won the lot, although no official confirmation yet.

PTH

Must be confirmed, buying going mad!

BioProgress PLC
01 October 2004



Press Release 1 October 2004


BioProgress Plc

('BioProgress' or the 'Company')

High Court victory for BioProgress in Patent Entitlement case


In a 100 per cent victory in a dispute with Stanelco Fibre Optics Limited,
BioProgress Technology Limited, a wholly owned subsidiary of BioProgress plc
(LSE: AIM: BPRG), has been awarded outright ownership of the master patent that
gives it exclusive worldwide rights to the process of making capsules from non-
gelatin materials by means of radio frequency ('RF').


This master patent controls the group of patents that were the subject of this
case and no commercial exploitation of the patented technology is permissible
without the consent of BioProgress.


The Court also found that discussions between BioProgress and Stanelco in the
summer of 1998 were subject to confidentiality. The Judge held that because
Stanelco had misused information given to them in confidence by BioProgress,
Stanelco had breached an obligation of confidence owed, by founding their own
family of patents and patent applications to the technology based on
BioProgress' core inventive concept.


There will now be a further hearing to determine the mechanism of transfer of
ownership of the main patent to BioProgress, together with all other patents and
patent applications worldwide which are derived from the original main patent
filing. In addition, the Court will be asked to assess the damages to be
awarded to BioProgress for Stanelco's misuse of BioProgress' confidential
information.


Graham Hind, CEO of BioProgress, said: 'This judgement validates the position we
have taken during the proceedings. The technology will strengthen significantly
our position in the global encapsulation market and adds significant revenue
earning potential to our SWALLOTM. liquid capsule technologies.


'By combining the intellectual property in this patent with our existing
technologies, BioProgress will now be able to deliver an even more
cost-effective, product enhancing, animal free solution to the encapsulation of
liquids which is a truly large global market.'


- Ends -

SEO will Appeal!

The uncertainty continues!

Commenting on the court's decision, Stanelco Chief Executive Ian Balchin said
'We are obviously pleased to have won outright on our entitlement to two of the
three patents families. We disagree with the court's reasoning in relation to
the remaining issues.

However, we believe that we have good prospects of
appealing the court's decision and this is the course we will be following.

Stanelco's business has continued to develop since the action was brought, with
a number of new applications for our RF technology - which do not rely upon
these patents. These include food tray lidding, which now represents a very
significant part of Stanelco's future projected revenues.'

Appeal, interesting can they afford it ?

Can't see the point in an appeal. More costs, if they lose, what's the point? They have a win of sorts, should move on. Wouldn't be surprised if the appeal comment was made in the heat of the moment and after further reflection and legal advice, they put the matter to rest. Would have bought some SEO when it was 28% down, alas no funds available!!

Regards

PTH

5:26 Fri 1 Oct 2004
BioProgress wins patent from Stanelco
Stanelco's shares have taken a knock on news that the High Court has ruled that BioProgress is the true owner of a key patent.


BioProgress (BPRG) boasts that it has had a '100%' victory after being awarded outright ownership of a master patent that gives it exclusive worldwide rights to the process of making non gelatine capsules using radio frequency.

Chief executive Graham Hind told Citywire: 'We've been vindicated in fighting this it will send a message out to others too.'

Stanelco took out a patent on technology for sealing cellulose capsules with radio frequencies following work it undertook for BioProgress.

The High Court has ruled that BioProgress has the right to this patent and also said Stanelco breached a confidentiality agreement, which is likely to have
to pay damages.

Most significantly for BioProgress, Stanelco (SEO) has a joint venture with health giant Cardinal Health using this technology to make pill casing, which is BioProgress' line of business. However the patent also relates to a number of other patents derived from this 'master' patent, although, it is not quite yet clear how far reaching BioProgress' victory will prove.

Rather astonishingly in its statement about the ruling Stanelco is claiming victory itself.

What Stanelco seems to be basing its strange notion of victory on is that it has been deemed to be the owner of two out of three patent families. It also says it will try to appeal the High Court's decision.

Unfortunately for Stanelco's shareholders the market seems to be taking a more conventional view on events and has sent the shares down 0.5p to 4.875p.

Stanelco's chief executive Ian Balchin said: ' Stanelco's business has continued to develop since the action was brought, with a number of new applications for our RF technology - which do not rely upon these patents. These include food tray lidding, which now represents a very significant part of Stanelco's future projected revenues.'

Hind said he was not entirely sure what the parts of Stanelco's business BioProgress can lay claim to. However, he said BioProgress will now be looking closely at Stanelco to see where its patent is being used.

There will be a further hearing to decide on how BioProgress will take ownership of the main patent and all other patents and patent applications, which are derived from the original filing. The court will also be asked to assess the damages to be awarded to BioProgress for Stanelcos misuse of BioProgress' confidential information.

In a separate announcement today BioProgress announced it would be raising up to 10 million with a convertible loan note on favourable terms. BioProgress already has cash balances of 13.3 million but said in the absence of any serious turnover or profits the strong balance sheet will help negotiations with potential big clients.

BioProgress' shares are up 7.5p to 128.5p.

Details of what technologies Stanelco will actually lose and what it will mean for the company should become clearer over the course of time, but it look as though the implications could be pretty severe. For the time being Citywire would recommend steering clear of the company especially as the ruling raises questions about management

http://tinyurl.com/6dpa6

I am still in BPRG and HOLDING :o) (good luck to all the OLD crew)

ps
i tipped ACE @ 102p now 178p ish SO listen next time :o)

anybody any views on SBRY long term?

aqa

Still in BPRG from 64.5p :)) and have added on the way up!

Jumpin - cut half in the long term account this week at 116p. Running the rest with stop currently at the quid.

The reaminder is now in almost for free. ;-)

Over the road has been quite hilarious on this subject. There's life, death and BPRG. Some people need to get a life! ;-0

I cut a few today.. well you can have too much of a good thing! And need to pay for the daily dose of champers...
;)

But am looking to buy them back again to pay for the next few cases

Hargreave Hale have issued a buy Note.

BioProgress Plc Buy
Company description: Patented encapsulation technology using water soluble film for tablets/pills/strips for dietary supplement, pharma, food and other sectors. The film is non-gelatin based and is heavily patented. Also, water soluble Ostomy Bag technology.

Bull points:
Industry-changing advantages, including new delivery mechanisms, and cost and
efficiency benefits
Claimed major industry shift away from gelatin-based encapsulation, driven by
desire to avoid animal-based materials (BSE, religious factors)
The company appears to be a true global trailblazer
Proprietary nature of machines and consumables
Substantial potential for profits and cash: machines up to $1.4m each,
generating up to $1m of revenues (with high margins) per annum
Deals and relationships with big Pharma players including Wyeth, Perrigo,
Bristol Myers Squibb
Impressive Chief executive; ambitious, imaginative, cautious, flexible,
strong enough to deal with Big Pharma-types
US roadshow in October, leading to ADR listing

Bear points:
Execution risk: BioProgress must close key global customers swiftly, and
prosecute manufacture efficiently
Apparent total reliance on CEO
One of the all-time AIM punter favourites: volatility

Investment summary and conclusion: BioProgress , remains one of the most exciting smaller companies around. The company appears to have truly disruptive technology: this is rare. They have a real shot at a leading position in substantial new markets.

Speculative, but with enormous potential: Buy.

Current Price 119.5p, Code BPRG, Mkt Cap 138m, High Risk

I believe BPRG have complained to the FSA about the inaccuracies in SEA RNS

Firm wins patents battle
02 October 2004

CHRIS STARKIE, EDP BUSINESS EDITOR

A hi-tech Fenland firm has won an important legal battle over the ownership of some of its pioneering technology.

A court has awarded March-based BioProgress outright ownership of the master patent that gives it exclusive worldwide rights to a particular way of making gelatine-free pill coatings.

BioProgress believes there is a massive market for the pill-coatings which are easier to swallow than conventional pills.

The judge found that Stanelco Fibre Optics had misused information given to them in confidence by BioProgress in 1998 when the two companies worked together, and awarded damages against Stanelco.

There will now be a further hearing to determine the level of damages awarded to BioProgress. The hearing will also determine how the main patent will be transferred to BioProgress.

Graham Hind, chief executive officer of BioProgress, said: "This judgment validates the position we have taken during the proceedings. The technology will strengthen significantly our position in the global encapsulation market and adds significant revenue earning potential to our SWALLO TM. liquid capsule technologies.

"By combining the intellectual property in this patent with our existing technologies, BioProgress will now be able to deliver an even more cost-effective, product enhancing, animal free solution to the encapsulation of liquids which is a truly large global market."

Fighting the court case had pushed BioProgress significantly into the red. Earlier this week it revealed a pre-tax loss of 3.8m for the year to June 30 after exceptional expenses of 4.4m.

These included consultancy fees and legal fees associated with the court case.

In a separate development BioProgress has raised 5m via a bond issue. The bonds have been placed with a leading institutional investor by broker Collins Stewart,

The institutional investor will also have an option to subscribe for up to a further 5m of the convertible bonds within the next two years.

Mr Hind said: "This bond issue has enabled us to strengthen our balance sheet further. It also represents a significant vote of confidence in BioProgress, which is reflected in the attractiveness of the terms we have achieved."


http://tinyurl.com/6bzcd

Just like to wish everyone good luck with this one especially nematode as he as stuck with it through thick and thin. I still hold a few tranches of stock but keep away from posting as this one seems to create far more than its fair share of arguments.

cheers GF.

at least discussions have been fairly civilised here unlike advfn